Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cardiol Therapeutics ( (TSE:CRDL) ) has provided an announcement.
On April 28, 2026, Cardiol Therapeutics announced it is expanding the U.S. clinical network for its pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis, reflecting strong investigator interest from leading cardiovascular centers such as Cleveland Clinic, Mayo Clinic, and Massachusetts General Hospital. Patient enrollment has reached 75%, with the company expecting to complete target recruitment by the end of the second quarter of 2026, potentially extending into the third quarter as up to seven additional U.S. sites are activated, positioning MAVERIC to generate the data needed to support a future U.S. regulatory filing and strengthen Cardiol’s standing in inflammatory heart disease therapeutics.
MAVERIC, a randomized, double-blind, placebo-controlled study designed with U.S. FDA input, builds on positive Phase II MAvERIC data that showed rapid, sustained reductions in pericarditis pain, inflammation, and recurrence rates. By broadening its trial footprint across premier academic hospitals and leveraging prior clinical results, Cardiol aims to establish CardiolRx™ as a non-immunosuppressive oral option earlier in the treatment pathway for recurrent pericarditis, potentially addressing a significant unmet need in a U.S. population where recurrent pericarditis imposes substantial morbidity and healthcare costs.
The most recent analyst rating on (TSE:CRDL) stock is a Buy with a C$8.00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.
Spark’s Take on CRDL Stock
According to Spark, TipRanks’ AI Analyst, CRDL is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, sizable losses, and sustained cash burn), partially offset by a low-debt balance sheet. Technicals are a positive contributor with an improving uptrend and constructive momentum, while valuation remains constrained due to negative earnings and no dividend support.
To see Spark’s full report on CRDL stock, click here.
More about Cardiol Therapeutics
Cardiol Therapeutics Inc. is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead small-molecule candidate, CardiolRx™, targets inflammasome pathway activation in conditions such as recurrent pericarditis, myocarditis, and heart failure, and the company is also advancing CRD-38 for inflammatory heart disease, including heart failure.
Average Trading Volume: 137,893
Technical Sentiment Signal: Buy
Current Market Cap: C$211.4M
See more insights into CRDL stock on TipRanks’ Stock Analysis page.